PRPH vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 17, 2026

PRPH

56.2
AI Score
VS
CDNA Wins

CDNA

65.0
AI Score

Investment Advisor Scores

PRPH

56score
Recommendation
HOLD

CDNA

65score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PRPH CDNA Winner
Revenue 1.17M 117.70M CDNA
Net Income -5.17M 2.81M CDNA
Net Margin -442.7% 2.4% CDNA
Operating Income -2.43M 1.20M CDNA
ROE 1189.7% 0.9% PRPH
ROA -8.9% 0.7% CDNA
Total Assets 58.47M 411.06M CDNA
Cash 31,000 77.92M CDNA
Current Ratio 0.05 3.40 CDNA

Relative Price Performance (Last 90 Days)

PRPH 1M: +157.2% · 3M: -29.6% CDNA 1M: +49.4% · 3M: +110.0%

Current Technical Phase

PRPH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 51.4 · Price: $0.36

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (23.4% over 20 days), RSI 77

RSI (14): 77.4 · Price: $43.71

Fundamentals Snapshot

Metric PRPH CDNA
Market Cap
Forward P/E 10.1 38.5
Trailing P/E
Revenue (TTM)
Revenue Growth -0.4% 0.4%
Gross Margin 0.2% 0.7%
Operating Margin -5.4% 0.0%
EPS -19.80 -0.17
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, CDNA is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.